Hengqu (hetrombopag) / Jiangsu Hengrui Pharma - LARVOL DELTA

Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Changhai Hospital

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management. (PubMed, Expert Opin Pharmacother) - "The three approved agents - romiplostim, eltrombopag, and avatrombopag - all stimulate the c-Mpl receptor but differ in their molecular interactions, pharmacokinetics, and potential immunomodulatory properties...TPO-RAs now represent a cornerstone of chronic ITP management and are expected to see broader use as growing evidence supports earlier and more individualized treatment strategies. Future progress will rely on personalized therapeutic strategies, informed monitoring, and AI-driven predictive tools that together may enhance remission durability and long-term clinical outcomes."

Journal • Review • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia. (PubMed, Hematology) - "A retrospective analysis was conducted on 50 patients with relapsed ITP, all of whom received TPO-RAs (hetrombopag and eltrombopag) combined with sirolimus therapy. The combination of TPO-RAs and sirolimus significantly improved platelet counts and sustained response rates. The regimen demonstrated a manageable safety profile, offering a novel therapeutic option for relapsed ITP."

Journal • Retrospective data • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

The Efficacy of a New Ladder-Type Anti-Human Thymocyte Immunoglobulin in the Treatment of Severe Aplastic Anemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi) - "The new stepped ATG regimen can not only ensure the efficacy, promote the recovery of bone marrow hematopoietic function, but also help reduce the side effects of ATG, and bring low-risk IST treatment opportunities for SAA patients."

Journal • Retrospective data • Anemia • Aplastic Anemia • Hematological Disorders

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd…received a notice from the National Medical Products Administration (NMPA). The NMPA approves the Company’s self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets, for adding a new indication. (HKEXnews) - "Approved indications: This product, in combination with immunosuppressive therapy, is indicated for patients aged 15 years and older with treatment-naive severe aplastic anemia (SAA)."

China approval • Aplastic Anemia

COMPARATIVE STUDY OF HETROMBOPAG VS. ELTROMBOPAG IN PROMOTING PLATELET ENGRAFTMENT POST-AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER CLINICAL TRIAL (EBMT 2026) - "This study is the first to demonstrate that hetrombopag significantly accelerates neutrophil and platelet engraftment in auto-HSCT patients compared to eltrombopag."

Clinical • Acute Myelogenous Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Nephrology • Non-Hodgkin’s Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation

COMPARATIVE STUDY OF HETROMBOPAG VS. ELTROMBOPAG IN PROMOTING PLATELET ENGRAFTMENT POST-AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER CLINICAL TRIAL (EBMT 2026) - "This study is the first to demonstrate that hetrombopag significantly accelerates neutrophil and platelet engraftment in auto-HSCT patients compared to eltrombopag."

Clinical • Acute Myelogenous Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Nephrology • Non-Hodgkin’s Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation

Longitudinal clinical and preclinical studies identify hetrombopag as a potent chelator for systemic iron overload. (PubMed, Hemasphere) - "Mechanistically, HPAG functions as a potential ferroptosis inhibitor by significantly reducing toxic iron accumulation, suppressing iron-induced lipid peroxidation at the cellular level, and alleviating systemic complications. These findings advance our understanding of transfusional IO and support the idea that targeting ferroptosis is a novel therapeutic strategy for systemic IO."

Journal • Preclinical • Aplastic Anemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

First-Line Hetrombopag Combined with Immunosuppressive Therapy for Pediatric Severe Aplastic Anemia: A Prospective Randomized Controlled Trial (ICKSH 2026) - No abstract available

Clinical • Anemia • Aplastic Anemia • Hematological Disorders • Pediatrics

Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis. (PubMed, Front Public Health) - "It dominates eltrombopag and offers a favorable economic profile compared with avatrombopag. These findings support the use of hetrombopag as a preferred option in resource-limited settings."

HEOR • Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Evaluation of the real-world efficacy of hetrombopag for the treatment of thrombocytopenia post allogeneic hematopoietic stem cell transplantation. (PubMed, Transplant Cell Ther) - "Hetrombopag demonstrates high efficacy and a favorable safety profile in the management of persistent thrombocytopenia after allo-HSCT, including in patients with poor megakaryocyte reserves or prior rhTPO failure. These real-world findings support its use as a promising therapeutic option in this high-risk population. Further prospective, randomized studies are needed to validate these results and establish predictive biomarkers for optimal patient selection."

Journal • Real-world evidence • Aplastic Anemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura • Transplantation • CD34

Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study (ASH 2025) - P=N/A | "Hetrombopag is effective in increasing platelet counts and demonstrates an acceptabletoxicity profile in LR-MDS patients with thrombocytopenia, suggesting that hetrombopag may be apromising new therapeutic option for this population. Nevertheless, further larger, prospective andcontrolled studies are warranted to better define the role of hetrombopag in the treatment of LR-MDS."

Clinical • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Hematological Disorders • Hematological Malignancies • Immune Thrombocytopenic Purpura • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Thrombocytopenia • Thrombocytopenic Purpura • ASXL1 • BCOR • DNMT3A • U2AF1

Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia. (PubMed, Front Immunol) - "Thrombopoietin receptor agonists combined with anti-thymocyte globulin (ATG) and cyclosporine (CsA) are the standard immunosuppressive therapy (IST) for severe/very severe aplastic anemia (SAA/VSAA)...Newly diagnosed SAA/VSAA patients received a combination treatment as follows: porcine ATG at 25 mg/kg/day from days 1 to 5, CsA at 3-5 mg/kg/day continuously, hetrombopag at 15 mg/day starting from day 1 and continued for 6 months, low-dose CTX at 20 mg/kg/day on days 29-30 and days 43-44...Infectious events occurred in 60.5% (26/43) of patients within the first 3 months of treatment, while no mortality observed during this period. Low-dose CTX combined with standard IST appears to improve the early response rate in SAA/VSAA patients with manageable toxicity."

Journal • Anemia • Aplastic Anemia • Hematological Disorders • Neutropenia

Hematopoiesis could be improved by correcting aberrant bone marrow macrophages polarization in aplastic anemia patients. (PubMed, Sci China Life Sci) - "To clarify the effect of thrombopoietin receptor agonist (TPO-RA) on BM MΦs polarization and subsequent impact on hematopoiesis and immunity, we established in vitro coculture assays of HSCs/T cells and BM MΦs treated with or without hetrombopag (HET), a novel TPO-RA...HET corrected the aberrant polarization of BM MΦs in AA patients and therefore improved their impaired functions, especially their hematopoiesis-supporting and immune-regulatory abilities, which may be related to the activation of the PI3K/AKT pathway. Although further validation is needed, our data suggest that remodeling BM MΦs polarization may be one of the reasons for the better clinical response to the combination of HET and IST in AA patients."

Journal • Anemia • Aplastic Anemia • Hematological Disorders • Transplantation

A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy (clinicaltrials.gov) - P2 | N=244 | Not yet recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

New P2 trial • Gynecologic Cancers • Hematological Disorders • Thrombocytopenia

A Multicenter, Single-Arm Exploratory Clinical Study on the Efficacy and Safety of Herombopag Olamine Tablets in Patients with Breast Cancer Experiencing Thrombocytopenia Induced by T-DM1 (ChiCTR) - P2 | N=56 | Recruiting | Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University

New P2 trial • Breast Cancer • Oncology • Solid Tumor • Thrombocytopenia

A multicenter, prospective, phase II clinical study of hytrombopag ethanolamine tablets combined with immunosuppressive therapy in newly diagnosed patients with non-severe aplastic anemia (ChiCTR) - P=N/A | N=76 | Not yet recruiting | Sponsor: Tianjin Medical University General Hospital; Tianjin Medical University General Hospital

New trial • Anemia • Aplastic Anemia • Hematological Disorders • Hematological Malignancies

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors. (PubMed, Res Pract Thromb Haemost) - "Safety profile showed good tolerability of hetrombopag (monotherapy or combined with rhTPO/rhIL-11) in patients. Hetrombopag may be an effective and well-tolerated treatment option for CIT in patients with solid tumors."

Journal • Review • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia

Efficacy and Safety of Herombopag Ethanolamine Tablets in Combination with Cyclosporine and Androgen for the Treatment of Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) Patients—A Single-Arm, Prospective, Multicenter Phase II Clinical Study (ChiCTR) - P4 | N=42 | Recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University

New P4 trial • Anemia • Aplastic Anemia • Hematological Disorders

No increased risk of hepatic enzyme abnormalities with non-peptidic thrombopoietin receptor agonists in immune thrombocytopenia: A meta-analysis of randomized controlled trials. (PubMed, Exp Ther Med) - "Non-peptidic thrombopoietin receptor agonists (TPO-RAs), including eltrombopag, avatrombopag and hetrombopag, are used as second-line therapies for immune thrombocytopenia (ITP). The present meta-analysis was registered in the International Prospective Register of Systematic Reviews (registration no. CRD420251084782)."

Journal • Retrospective data • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Long-term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia. (PubMed, Br J Haematol) - "Furthermore, among the nine patients who switched from other TPO-RAs, seven patients achieved OR during initial treatment, including three patients who achieved CR and four patients who achieved R. The overall incidence of adverse events was 37.6%, with no serious adverse events reported. Our findings highlight that hetrombopag is both safe and effective in paediatric patients and may serve as a viable option for patients for whom first-line therapy fails."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Pediatrics • Thrombocytopenia • Thrombocytopenic Purpura

A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients. (clinicaltrials.gov) - P2 | N=204 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P2 trial • Oncology • Solid Tumor • Thrombocytopenia

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial. (PubMed, Am J Hematol) - P2 | "Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies. Importantly, no clonal progression to myelodysplastic syndrome or leukemia was observed. These findings support hetrombopag plus CsA as a potential first-line therapeutic intervention for NSAA, especially in TD-NSAA patients."

Journal • P2 data • Anemia • Aplastic Anemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (clinicaltrials.gov) - P3 | N=150 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P3 trial • Hematological Disorders • Neutropenia • Thrombocytopenia

Hetrombopag for enhancing platelet engraftment after haploidentical allogeneic hematopoietic stem cell transplantation in patients with severe thalassemia: An observational study (ASH 2025) - P | "Graft-versus-host disease prophylaxis included cyclophosphamide at a total dose of 100 mg/kg (divided into two doses on day +3 and +4), methotrexate at 10 mg/m² (administered on days +1, +2, +5, and +6), and cyclosporine A at 4 mg/kg/day starting from day +6. A significant difference in transfusion volume between groups may have introduced bias in post-transplant outcome analysis. These findings suggest that relying solely on platelet engraftment time as a measure of engraftment efficacy may be inadequate and potentially limiting."

Clinical • Observational data • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Liver Failure • Musculoskeletal Pain • Nephrology • Transplantation